Since AP - 1 and NF - kappa B are key elements in controlling interleukin - 8 ( IL - 8) transcription, human fibroblasts were treated with alpha - MSH and IL - 1 beta for 24 hours, and cytokine levels in the supernatants were measured by ELISA.	"AP - 1	6	12	Gene_or_gene_product"	"NF - kappa B	17	29	Gene_or_gene_product"	"interleukin - 8	62	77	Gene_or_gene_product"	"IL - 8	80	86	Gene_or_gene_product"	"alpha - MSH	139	150	Gene_or_gene_product"	"IL - 1 beta	155	166	Gene_or_gene_product"	"[{""token"": ""AP - 1"", ""start_span"": 6, ""end_span"": 12, ""type"": ""Gene_or_gene_product""}, {""token"": ""NF - kappa B"", ""start_span"": 17, ""end_span"": 29, ""type"": ""Gene_or_gene_product""}, {""token"": ""interleukin - 8"", ""start_span"": 62, ""end_span"": 77, ""type"": ""Gene_or_gene_product""}, {""token"": ""IL - 8"", ""start_span"": 80, ""end_span"": 86, ""type"": ""Gene_or_gene_product""}, {""token"": ""alpha - MSH"", ""start_span"": 139, ""end_span"": 150, ""type"": ""Gene_or_gene_product""}, {""token"": ""IL - 1 beta"", ""start_span"": 155, ""end_span"": 166, ""type"": ""Gene_or_gene_product""}]"
METHODS: Using flow cytometry we evaluated 18 human lung cancer cell lines for the expression of different surface markers on lung cancers suggested to be possible prognostic parameters, including epidermal growth factor receptor ( EGFR), intercellular adhesion molecule 1 ( ICAM - 1), Fas and CD40.	"epidermal growth factor receptor	197	229	Gene_or_gene_product"	"EGFR	232	236	Gene_or_gene_product"	"intercellular adhesion molecule 1	239	272	Gene_or_gene_product"	"ICAM - 1	275	283	Gene_or_gene_product"	"Fas	286	289	Gene_or_gene_product"	"CD40	294	298	Gene_or_gene_product"	"[{""token"": ""epidermal growth factor receptor"", ""start_span"": 197, ""end_span"": 229, ""type"": ""Gene_or_gene_product""}, {""token"": ""EGFR"", ""start_span"": 232, ""end_span"": 236, ""type"": ""Gene_or_gene_product""}, {""token"": ""intercellular adhesion molecule 1"", ""start_span"": 239, ""end_span"": 272, ""type"": ""Gene_or_gene_product""}, {""token"": ""ICAM - 1"", ""start_span"": 275, ""end_span"": 283, ""type"": ""Gene_or_gene_product""}, {""token"": ""Fas"", ""start_span"": 286, ""end_span"": 289, ""type"": ""Gene_or_gene_product""}, {""token"": ""CD40"", ""start_span"": 294, ""end_span"": 298, ""type"": ""Gene_or_gene_product""}]"
The therapeutic options available in this regard include measures that: down - regulate serum free IGF - I; suppress the synthesis of mevalonic acid and / or certain derivatives thereof; modulate arachidonate metabolism by inhibiting 5 - lipoxygenase, 12 - lipoxygenase, or COX - 2; antagonize the activation of AP - 1 transcription factors; promote the activation of PPAR - gamma transcription factors; and that suppress angiogenesis by additional mechanisms.	"IGF - I	99	106	Gene_or_gene_product"	"5 - lipoxygenase	234	250	Gene_or_gene_product"	"12 - lipoxygenase	252	269	Gene_or_gene_product"	"COX - 2	274	281	Gene_or_gene_product"	"AP - 1	312	318	Gene_or_gene_product"	"PPAR - gamma	368	380	Gene_or_gene_product"	"[{""token"": ""IGF - I"", ""start_span"": 99, ""end_span"": 106, ""type"": ""Gene_or_gene_product""}, {""token"": ""5 - lipoxygenase"", ""start_span"": 234, ""end_span"": 250, ""type"": ""Gene_or_gene_product""}, {""token"": ""12 - lipoxygenase"", ""start_span"": 252, ""end_span"": 269, ""type"": ""Gene_or_gene_product""}, {""token"": ""COX - 2"", ""start_span"": 274, ""end_span"": 281, ""type"": ""Gene_or_gene_product""}, {""token"": ""AP - 1"", ""start_span"": 312, ""end_span"": 318, ""type"": ""Gene_or_gene_product""}, {""token"": ""PPAR - gamma"", ""start_span"": 368, ""end_span"": 380, ""type"": ""Gene_or_gene_product""}]"
A specific histone deacetylase ( HDAc) inhibitor, trichostatin A ( TSA), alleviates Evi - 1 - mediated repression of TGF - beta signaling, suggesting that HDAc is involved in transcriptional repression by Evi - 1.	"histone deacetylase	11	30	Gene_or_gene_product"	"HDAc	33	37	Gene_or_gene_product"	"Evi - 1	84	91	Gene_or_gene_product"	"TGF - beta	117	127	Gene_or_gene_product"	"HDAc	155	159	Gene_or_gene_product"	"Evi - 1	205	212	Gene_or_gene_product"	"[{""token"": ""histone deacetylase"", ""start_span"": 11, ""end_span"": 30, ""type"": ""Gene_or_gene_product""}, {""token"": ""HDAc"", ""start_span"": 33, ""end_span"": 37, ""type"": ""Gene_or_gene_product""}, {""token"": ""Evi - 1"", ""start_span"": 84, ""end_span"": 91, ""type"": ""Gene_or_gene_product""}, {""token"": ""TGF - beta"", ""start_span"": 117, ""end_span"": 127, ""type"": ""Gene_or_gene_product""}, {""token"": ""HDAc"", ""start_span"": 155, ""end_span"": 159, ""type"": ""Gene_or_gene_product""}, {""token"": ""Evi - 1"", ""start_span"": 205, ""end_span"": 212, ""type"": ""Gene_or_gene_product""}]"
Cyclin - dependent kinase - 2 activity, p107 and cyclin A levels, and retinoblastoma protein phosphorylation are markedly reduced in response to the addition of exogenous SPARC and / or peptides derived from specific domains of SPARC.	"Cyclin - dependent kinase - 2	0	29	Gene_or_gene_product"	"p107	40	44	Gene_or_gene_product"	"cyclin A	49	57	Gene_or_gene_product"	"retinoblastoma protein	70	92	Gene_or_gene_product"	"SPARC	171	176	Gene_or_gene_product"	"SPARC	228	233	Gene_or_gene_product"	"[{""token"": ""Cyclin - dependent kinase - 2"", ""start_span"": 0, ""end_span"": 29, ""type"": ""Gene_or_gene_product""}, {""token"": ""p107"", ""start_span"": 40, ""end_span"": 44, ""type"": ""Gene_or_gene_product""}, {""token"": ""cyclin A"", ""start_span"": 49, ""end_span"": 57, ""type"": ""Gene_or_gene_product""}, {""token"": ""retinoblastoma protein"", ""start_span"": 70, ""end_span"": 92, ""type"": ""Gene_or_gene_product""}, {""token"": ""SPARC"", ""start_span"": 171, ""end_span"": 176, ""type"": ""Gene_or_gene_product""}, {""token"": ""SPARC"", ""start_span"": 228, ""end_span"": 233, ""type"": ""Gene_or_gene_product""}]"
Treatment of REF or REF expressing full - length T antigen, an N - terminal segment, or T251 - 708 resulted in increased expression of the p53 - responsive MDM2 gene; apoptosis occurred through a p53 - dependent pathway, as p53 - null cells expressing these T antigens were resistant to 5 - FU - induced apoptosis.	"T antigen	49	58	Gene_or_gene_product"	"p53	139	142	Gene_or_gene_product"	"MDM2	156	160	Gene_or_gene_product"	"p53	196	199	Gene_or_gene_product"	"p53	224	227	Gene_or_gene_product"	"T antigens	258	268	Gene_or_gene_product"	"[{""token"": ""T antigen"", ""start_span"": 49, ""end_span"": 58, ""type"": ""Gene_or_gene_product""}, {""token"": ""p53"", ""start_span"": 139, ""end_span"": 142, ""type"": ""Gene_or_gene_product""}, {""token"": ""MDM2"", ""start_span"": 156, ""end_span"": 160, ""type"": ""Gene_or_gene_product""}, {""token"": ""p53"", ""start_span"": 196, ""end_span"": 199, ""type"": ""Gene_or_gene_product""}, {""token"": ""p53"", ""start_span"": 224, ""end_span"": 227, ""type"": ""Gene_or_gene_product""}, {""token"": ""T antigens"", ""start_span"": 258, ""end_span"": 268, ""type"": ""Gene_or_gene_product""}]"
Western blotting of p53 and murine double mutant 2 ( Mdm2) together with p53 DNA sequencing analysis indicate that p53 function loss by mutation or overexpression of Mdm2 occurred in all tested oral cancer cells regardless of their etiology.	"p53	20	23	Gene_or_gene_product"	"murine double mutant 2	28	50	Gene_or_gene_product"	"Mdm2	53	57	Gene_or_gene_product"	"p53	73	76	Gene_or_gene_product"	"p53	115	118	Gene_or_gene_product"	"Mdm2	166	170	Gene_or_gene_product"	"[{""token"": ""p53"", ""start_span"": 20, ""end_span"": 23, ""type"": ""Gene_or_gene_product""}, {""token"": ""murine double mutant 2"", ""start_span"": 28, ""end_span"": 50, ""type"": ""Gene_or_gene_product""}, {""token"": ""Mdm2"", ""start_span"": 53, ""end_span"": 57, ""type"": ""Gene_or_gene_product""}, {""token"": ""p53"", ""start_span"": 73, ""end_span"": 76, ""type"": ""Gene_or_gene_product""}, {""token"": ""p53"", ""start_span"": 115, ""end_span"": 118, ""type"": ""Gene_or_gene_product""}, {""token"": ""Mdm2"", ""start_span"": 166, ""end_span"": 170, ""type"": ""Gene_or_gene_product""}]"
Looking for mechanisms linking Brn - 3a to carcinogenesis, we discuss the role of this transcription factor in influencing Bcl - 2 / p53 antagonism and Bcl - 2 / VEGF induction of tumor angiogenesis, concluding this review with a proposal for the oncogenic nature of Brn - 3a.	"Brn - 3a	31	39	Gene_or_gene_product"	"Bcl - 2	123	130	Gene_or_gene_product"	"p53	133	136	Gene_or_gene_product"	"Bcl - 2	152	159	Gene_or_gene_product"	"VEGF	162	166	Gene_or_gene_product"	"Brn - 3a	267	275	Gene_or_gene_product"	"[{""token"": ""Brn - 3a"", ""start_span"": 31, ""end_span"": 39, ""type"": ""Gene_or_gene_product""}, {""token"": ""Bcl - 2"", ""start_span"": 123, ""end_span"": 130, ""type"": ""Gene_or_gene_product""}, {""token"": ""p53"", ""start_span"": 133, ""end_span"": 136, ""type"": ""Gene_or_gene_product""}, {""token"": ""Bcl - 2"", ""start_span"": 152, ""end_span"": 159, ""type"": ""Gene_or_gene_product""}, {""token"": ""VEGF"", ""start_span"": 162, ""end_span"": 166, ""type"": ""Gene_or_gene_product""}, {""token"": ""Brn - 3a"", ""start_span"": 267, ""end_span"": 275, ""type"": ""Gene_or_gene_product""}]"
Because there is little information on the expression of topo I in colorectal tumors, this study evaluated and characterized topo I protein expression in primary colorectal cancer and lymph node metastases and studied the association between topo I protein expression and clinicopathologic data, p53 status, and proliferating cell nuclear antigen ( PCNA) status.	"topo I	57	63	Gene_or_gene_product"	"topo I	125	131	Gene_or_gene_product"	"topo I	242	248	Gene_or_gene_product"	"p53	296	299	Gene_or_gene_product"	"proliferating cell nuclear antigen	312	346	Gene_or_gene_product"	"PCNA	349	353	Gene_or_gene_product"	"[{""token"": ""topo I"", ""start_span"": 57, ""end_span"": 63, ""type"": ""Gene_or_gene_product""}, {""token"": ""topo I"", ""start_span"": 125, ""end_span"": 131, ""type"": ""Gene_or_gene_product""}, {""token"": ""topo I"", ""start_span"": 242, ""end_span"": 248, ""type"": ""Gene_or_gene_product""}, {""token"": ""p53"", ""start_span"": 296, ""end_span"": 299, ""type"": ""Gene_or_gene_product""}, {""token"": ""proliferating cell nuclear antigen"", ""start_span"": 312, ""end_span"": 346, ""type"": ""Gene_or_gene_product""}, {""token"": ""PCNA"", ""start_span"": 349, ""end_span"": 353, ""type"": ""Gene_or_gene_product""}]"
Experimental Design: Human umbilical vein and dermal microvascular endothelial cells were infected with replication - deficient adenoviruses encoding survivin ( pAd - Survivin), green fluorescent protein ( pAd - GFP), or a phosphorylation - defective survivin Thr ( 34) - - > Ala ( pAd - T34A) dominant negative mutant.	"survivin	150	158	Gene_or_gene_product"	"pAd - Survivin	161	175	Gene_or_gene_product"	"green fluorescent protein	178	203	Gene_or_gene_product"	"pAd - GFP	206	215	Gene_or_gene_product"	"survivin	251	259	Gene_or_gene_product"	"pAd - T34A	282	292	Gene_or_gene_product"	"[{""token"": ""survivin"", ""start_span"": 150, ""end_span"": 158, ""type"": ""Gene_or_gene_product""}, {""token"": ""pAd - Survivin"", ""start_span"": 161, ""end_span"": 175, ""type"": ""Gene_or_gene_product""}, {""token"": ""green fluorescent protein"", ""start_span"": 178, ""end_span"": 203, ""type"": ""Gene_or_gene_product""}, {""token"": ""pAd - GFP"", ""start_span"": 206, ""end_span"": 215, ""type"": ""Gene_or_gene_product""}, {""token"": ""survivin"", ""start_span"": 251, ""end_span"": 259, ""type"": ""Gene_or_gene_product""}, {""token"": ""pAd - T34A"", ""start_span"": 282, ""end_span"": 292, ""type"": ""Gene_or_gene_product""}]"
We show that ING4 physically interacts with p65 ( RelA) subunit of nuclear factor NF - kappaB, and that ING4 regulates brain tumour angiogenesis through transcriptional repression of NF - kappaB - responsive genes.	"ING4	13	17	Gene_or_gene_product"	"p65	44	47	Gene_or_gene_product"	"RelA	50	54	Gene_or_gene_product"	"NF - kappaB	82	93	Gene_or_gene_product"	"ING4	104	108	Gene_or_gene_product"	"NF - kappaB	183	194	Gene_or_gene_product"	"[{""token"": ""ING4"", ""start_span"": 13, ""end_span"": 17, ""type"": ""Gene_or_gene_product""}, {""token"": ""p65"", ""start_span"": 44, ""end_span"": 47, ""type"": ""Gene_or_gene_product""}, {""token"": ""RelA"", ""start_span"": 50, ""end_span"": 54, ""type"": ""Gene_or_gene_product""}, {""token"": ""NF - kappaB"", ""start_span"": 82, ""end_span"": 93, ""type"": ""Gene_or_gene_product""}, {""token"": ""ING4"", ""start_span"": 104, ""end_span"": 108, ""type"": ""Gene_or_gene_product""}, {""token"": ""NF - kappaB"", ""start_span"": 183, ""end_span"": 194, ""type"": ""Gene_or_gene_product""}]"
In this study, to examine hypoxia - specific production of anti - angiogenic therapeutic gene, we constructed 5 copies of HRE ( 5xHRE) of human VEGF linked to soluble Tie2 ( sTie2) driven by minimal SV40 promoter ( 5xHRE / SV40 / sTie2).	"VEGF	144	148	Gene_or_gene_product"	"Tie2	167	171	Gene_or_gene_product"	"sTie2	174	179	Gene_or_gene_product"	"SV40	199	203	Gene_or_gene_product"	"SV40	223	227	Gene_or_gene_product"	"sTie2	230	235	Gene_or_gene_product"	"[{""token"": ""VEGF"", ""start_span"": 144, ""end_span"": 148, ""type"": ""Gene_or_gene_product""}, {""token"": ""Tie2"", ""start_span"": 167, ""end_span"": 171, ""type"": ""Gene_or_gene_product""}, {""token"": ""sTie2"", ""start_span"": 174, ""end_span"": 179, ""type"": ""Gene_or_gene_product""}, {""token"": ""SV40"", ""start_span"": 199, ""end_span"": 203, ""type"": ""Gene_or_gene_product""}, {""token"": ""SV40"", ""start_span"": 223, ""end_span"": 227, ""type"": ""Gene_or_gene_product""}, {""token"": ""sTie2"", ""start_span"": 230, ""end_span"": 235, ""type"": ""Gene_or_gene_product""}]"
In addition to p16 ( INK4A), the INK4A locus encodes a splice variant, termed p12 - - specifically expressed in human pancreas - - and ARF, a protein encoded by an alternative reading frame that acts as a tumor suppressor through the p53 pathway.	"p16	15	18	Gene_or_gene_product"	"INK4A	21	26	Gene_or_gene_product"	"INK4A	33	38	Gene_or_gene_product"	"p12	78	81	Gene_or_gene_product"	"ARF	135	138	Gene_or_gene_product"	"p53	234	237	Gene_or_gene_product"	"[{""token"": ""p16"", ""start_span"": 15, ""end_span"": 18, ""type"": ""Gene_or_gene_product""}, {""token"": ""INK4A"", ""start_span"": 21, ""end_span"": 26, ""type"": ""Gene_or_gene_product""}, {""token"": ""INK4A"", ""start_span"": 33, ""end_span"": 38, ""type"": ""Gene_or_gene_product""}, {""token"": ""p12"", ""start_span"": 78, ""end_span"": 81, ""type"": ""Gene_or_gene_product""}, {""token"": ""ARF"", ""start_span"": 135, ""end_span"": 138, ""type"": ""Gene_or_gene_product""}, {""token"": ""p53"", ""start_span"": 234, ""end_span"": 237, ""type"": ""Gene_or_gene_product""}]"
Inhibitors of Akt and P13 - kinase, the upstream activator of Akt, block endothelial cell migration and disrupt paxillin localization to the focal adhesions after stimulation with VEGF and S1P.	"Akt	14	17	Gene_or_gene_product"	"P13 - kinase	22	34	Gene_or_gene_product"	"Akt	62	65	Gene_or_gene_product"	"paxillin	112	120	Gene_or_gene_product"	"VEGF	180	184	Gene_or_gene_product"	"S1P	189	192	Gene_or_gene_product"	"[{""token"": ""Akt"", ""start_span"": 14, ""end_span"": 17, ""type"": ""Gene_or_gene_product""}, {""token"": ""P13 - kinase"", ""start_span"": 22, ""end_span"": 34, ""type"": ""Gene_or_gene_product""}, {""token"": ""Akt"", ""start_span"": 62, ""end_span"": 65, ""type"": ""Gene_or_gene_product""}, {""token"": ""paxillin"", ""start_span"": 112, ""end_span"": 120, ""type"": ""Gene_or_gene_product""}, {""token"": ""VEGF"", ""start_span"": 180, ""end_span"": 184, ""type"": ""Gene_or_gene_product""}, {""token"": ""S1P"", ""start_span"": 189, ""end_span"": 192, ""type"": ""Gene_or_gene_product""}]"
Inhibition of c - Jun amino - terminal kinase ( JNK) blocked type III collagen expression in LRP - 1 - deficient MEFs, suggesting regulation of JNK activity as a mechanism by which LRP - 1 controls mRNA expression.	"c - Jun amino - terminal kinase	14	45	Gene_or_gene_product"	"JNK	48	51	Gene_or_gene_product"	"type III collagen	61	78	Gene_or_gene_product"	"LRP - 1	93	100	Gene_or_gene_product"	"JNK	144	147	Gene_or_gene_product"	"LRP - 1	181	188	Gene_or_gene_product"	"[{""token"": ""c - Jun amino - terminal kinase"", ""start_span"": 14, ""end_span"": 45, ""type"": ""Gene_or_gene_product""}, {""token"": ""JNK"", ""start_span"": 48, ""end_span"": 51, ""type"": ""Gene_or_gene_product""}, {""token"": ""type III collagen"", ""start_span"": 61, ""end_span"": 78, ""type"": ""Gene_or_gene_product""}, {""token"": ""LRP - 1"", ""start_span"": 93, ""end_span"": 100, ""type"": ""Gene_or_gene_product""}, {""token"": ""JNK"", ""start_span"": 144, ""end_span"": 147, ""type"": ""Gene_or_gene_product""}, {""token"": ""LRP - 1"", ""start_span"": 181, ""end_span"": 188, ""type"": ""Gene_or_gene_product""}]"
PCNSLs with HRK methylation also showed methylation of multiple genes, such as p14ARF, p16INK4a, RB1, p27Kip1 and O6 - MGMT.	"HRK	12	15	Gene_or_gene_product"	"p14ARF	79	85	Gene_or_gene_product"	"p16INK4a	87	95	Gene_or_gene_product"	"RB1	97	100	Gene_or_gene_product"	"p27Kip1	102	109	Gene_or_gene_product"	"O6 - MGMT	114	123	Gene_or_gene_product"	"[{""token"": ""HRK"", ""start_span"": 12, ""end_span"": 15, ""type"": ""Gene_or_gene_product""}, {""token"": ""p14ARF"", ""start_span"": 79, ""end_span"": 85, ""type"": ""Gene_or_gene_product""}, {""token"": ""p16INK4a"", ""start_span"": 87, ""end_span"": 95, ""type"": ""Gene_or_gene_product""}, {""token"": ""RB1"", ""start_span"": 97, ""end_span"": 100, ""type"": ""Gene_or_gene_product""}, {""token"": ""p27Kip1"", ""start_span"": 102, ""end_span"": 109, ""type"": ""Gene_or_gene_product""}, {""token"": ""O6 - MGMT"", ""start_span"": 114, ""end_span"": 123, ""type"": ""Gene_or_gene_product""}]"
Mutant mice lacking both cyclin - dependent kinase ( CDK) inhibitors p18 ( Ink4c) and p27 ( Kip1) develop a tumor spectrum reminiscent of human multiple endocrine neoplasia ( MEN) syndromes.	"cyclin - dependent kinase	25	50	Gene_or_gene_product"	"CDK	53	56	Gene_or_gene_product"	"p18	69	72	Gene_or_gene_product"	"Ink4c	75	80	Gene_or_gene_product"	"p27	86	89	Gene_or_gene_product"	"Kip1	92	96	Gene_or_gene_product"	"[{""token"": ""cyclin - dependent kinase"", ""start_span"": 25, ""end_span"": 50, ""type"": ""Gene_or_gene_product""}, {""token"": ""CDK"", ""start_span"": 53, ""end_span"": 56, ""type"": ""Gene_or_gene_product""}, {""token"": ""p18"", ""start_span"": 69, ""end_span"": 72, ""type"": ""Gene_or_gene_product""}, {""token"": ""Ink4c"", ""start_span"": 75, ""end_span"": 80, ""type"": ""Gene_or_gene_product""}, {""token"": ""p27"", ""start_span"": 86, ""end_span"": 89, ""type"": ""Gene_or_gene_product""}, {""token"": ""Kip1"", ""start_span"": 92, ""end_span"": 96, ""type"": ""Gene_or_gene_product""}]"
Trib1 and Evi1 were up - regulated due to retroviral insertions, and coexpression of these genes significantly accelerated the onset of Hoxa9 / Meis1 - induced AML, suggesting that Trib1 and Evi1 are the key collaborators.	"Trib1	0	5	Gene_or_gene_product"	"Evi1	10	14	Gene_or_gene_product"	"Hoxa9	136	141	Gene_or_gene_product"	"Meis1	144	149	Gene_or_gene_product"	"Trib1	181	186	Gene_or_gene_product"	"Evi1	191	195	Gene_or_gene_product"	"[{""token"": ""Trib1"", ""start_span"": 0, ""end_span"": 5, ""type"": ""Gene_or_gene_product""}, {""token"": ""Evi1"", ""start_span"": 10, ""end_span"": 14, ""type"": ""Gene_or_gene_product""}, {""token"": ""Hoxa9"", ""start_span"": 136, ""end_span"": 141, ""type"": ""Gene_or_gene_product""}, {""token"": ""Meis1"", ""start_span"": 144, ""end_span"": 149, ""type"": ""Gene_or_gene_product""}, {""token"": ""Trib1"", ""start_span"": 181, ""end_span"": 186, ""type"": ""Gene_or_gene_product""}, {""token"": ""Evi1"", ""start_span"": 191, ""end_span"": 195, ""type"": ""Gene_or_gene_product""}]"
The induction of vascular endothelial growth factor ( VEGF) and interleukin - 8 ( IL - 8) is an essential feature of tumor angiogenesis, and the hypoxia - inducible factor - 1 ( HIF - 1) transcription factor is known to be a key regulator of this process.	"vascular endothelial growth factor	17	51	Gene_or_gene_product"	"VEGF	54	58	Gene_or_gene_product"	"interleukin - 8	64	79	Gene_or_gene_product"	"IL - 8	82	88	Gene_or_gene_product"	"hypoxia - inducible factor - 1	145	175	Gene_or_gene_product"	"HIF - 1	178	185	Gene_or_gene_product"	"[{""token"": ""vascular endothelial growth factor"", ""start_span"": 17, ""end_span"": 51, ""type"": ""Gene_or_gene_product""}, {""token"": ""VEGF"", ""start_span"": 54, ""end_span"": 58, ""type"": ""Gene_or_gene_product""}, {""token"": ""interleukin - 8"", ""start_span"": 64, ""end_span"": 79, ""type"": ""Gene_or_gene_product""}, {""token"": ""IL - 8"", ""start_span"": 82, ""end_span"": 88, ""type"": ""Gene_or_gene_product""}, {""token"": ""hypoxia - inducible factor - 1"", ""start_span"": 145, ""end_span"": 175, ""type"": ""Gene_or_gene_product""}, {""token"": ""HIF - 1"", ""start_span"": 178, ""end_span"": 185, ""type"": ""Gene_or_gene_product""}]"
Furthermore, there is strong evidence suggesting that aberrant activation of Wnt signaling induces mammary tumors from stem / progenitor cells, and that Wnt exerts its oncogenic effects through LRP5 / 6 - mediated activation of beta - catenin and mTOR pathways.	"Wnt	77	80	Gene_or_gene_product"	"Wnt	153	156	Gene_or_gene_product"	"LRP5	194	198	Gene_or_gene_product"	"6	201	202	Gene_or_gene_product"	"beta - catenin	228	242	Gene_or_gene_product"	"mTOR	247	251	Gene_or_gene_product"	"[{""token"": ""Wnt"", ""start_span"": 77, ""end_span"": 80, ""type"": ""Gene_or_gene_product""}, {""token"": ""Wnt"", ""start_span"": 153, ""end_span"": 156, ""type"": ""Gene_or_gene_product""}, {""token"": ""LRP5"", ""start_span"": 194, ""end_span"": 198, ""type"": ""Gene_or_gene_product""}, {""token"": ""6"", ""start_span"": 201, ""end_span"": 202, ""type"": ""Gene_or_gene_product""}, {""token"": ""beta - catenin"", ""start_span"": 228, ""end_span"": 242, ""type"": ""Gene_or_gene_product""}, {""token"": ""mTOR"", ""start_span"": 247, ""end_span"": 251, ""type"": ""Gene_or_gene_product""}]"
These cells were negative for Hep par - 1, carcinoembryonic antigen, neural cell adhesion molecule, CD34, CD31 and HMB45.	"Hep par - 1	30	41	Gene_or_gene_product"	"carcinoembryonic antigen	43	67	Gene_or_gene_product"	"neural cell adhesion molecule	69	98	Gene_or_gene_product"	"CD34	100	104	Gene_or_gene_product"	"CD31	106	110	Gene_or_gene_product"	"HMB45	115	120	Gene_or_gene_product"	"[{""token"": ""Hep par - 1"", ""start_span"": 30, ""end_span"": 41, ""type"": ""Gene_or_gene_product""}, {""token"": ""carcinoembryonic antigen"", ""start_span"": 43, ""end_span"": 67, ""type"": ""Gene_or_gene_product""}, {""token"": ""neural cell adhesion molecule"", ""start_span"": 69, ""end_span"": 98, ""type"": ""Gene_or_gene_product""}, {""token"": ""CD34"", ""start_span"": 100, ""end_span"": 104, ""type"": ""Gene_or_gene_product""}, {""token"": ""CD31"", ""start_span"": 106, ""end_span"": 110, ""type"": ""Gene_or_gene_product""}, {""token"": ""HMB45"", ""start_span"": 115, ""end_span"": 120, ""type"": ""Gene_or_gene_product""}]"
Using a construct containing the VEGF promoter linked to a luciferase reporter, we found that a mutation reducing HIF binding to the VEGF promoter had no significant effect on luciferase production induced by M - CSF stimulation.	"VEGF	33	37	Gene_or_gene_product"	"luciferase	59	69	Gene_or_gene_product"	"HIF	114	117	Gene_or_gene_product"	"VEGF	133	137	Gene_or_gene_product"	"luciferase	176	186	Gene_or_gene_product"	"M - CSF	209	216	Gene_or_gene_product"	"[{""token"": ""VEGF"", ""start_span"": 33, ""end_span"": 37, ""type"": ""Gene_or_gene_product""}, {""token"": ""luciferase"", ""start_span"": 59, ""end_span"": 69, ""type"": ""Gene_or_gene_product""}, {""token"": ""HIF"", ""start_span"": 114, ""end_span"": 117, ""type"": ""Gene_or_gene_product""}, {""token"": ""VEGF"", ""start_span"": 133, ""end_span"": 137, ""type"": ""Gene_or_gene_product""}, {""token"": ""luciferase"", ""start_span"": 176, ""end_span"": 186, ""type"": ""Gene_or_gene_product""}, {""token"": ""M - CSF"", ""start_span"": 209, ""end_span"": 216, ""type"": ""Gene_or_gene_product""}]"
CONCLUSION: These data delineate an ERK - and Sp1 - dependent mechanism of M - CSF induced VEGF production and demonstrate for the first time the ability of M - CSF to induce angiogenesis via VEGF in vivo.	"ERK	36	39	Gene_or_gene_product"	"Sp1	46	49	Gene_or_gene_product"	"M - CSF	75	82	Gene_or_gene_product"	"VEGF	91	95	Gene_or_gene_product"	"M - CSF	157	164	Gene_or_gene_product"	"VEGF	192	196	Gene_or_gene_product"	"[{""token"": ""ERK"", ""start_span"": 36, ""end_span"": 39, ""type"": ""Gene_or_gene_product""}, {""token"": ""Sp1"", ""start_span"": 46, ""end_span"": 49, ""type"": ""Gene_or_gene_product""}, {""token"": ""M - CSF"", ""start_span"": 75, ""end_span"": 82, ""type"": ""Gene_or_gene_product""}, {""token"": ""VEGF"", ""start_span"": 91, ""end_span"": 95, ""type"": ""Gene_or_gene_product""}, {""token"": ""M - CSF"", ""start_span"": 157, ""end_span"": 164, ""type"": ""Gene_or_gene_product""}, {""token"": ""VEGF"", ""start_span"": 192, ""end_span"": 196, ""type"": ""Gene_or_gene_product""}]"
RESULTS: PCR and chimeric BMP - 2 and BMP - 4 luciferase assays demonstrate that NF - kappaB confers robust and selective activation of BMP - 2 in p65 overexpressing or rhTNF - alpha - stimulated PC cells.	"BMP - 2	26	33	Gene_or_gene_product"	"BMP - 4	38	45	Gene_or_gene_product"	"NF - kappaB	81	92	Gene_or_gene_product"	"BMP - 2	136	143	Gene_or_gene_product"	"p65	147	150	Gene_or_gene_product"	"rhTNF - alpha	169	182	Gene_or_gene_product"	"[{""token"": ""BMP - 2"", ""start_span"": 26, ""end_span"": 33, ""type"": ""Gene_or_gene_product""}, {""token"": ""BMP - 4"", ""start_span"": 38, ""end_span"": 45, ""type"": ""Gene_or_gene_product""}, {""token"": ""NF - kappaB"", ""start_span"": 81, ""end_span"": 92, ""type"": ""Gene_or_gene_product""}, {""token"": ""BMP - 2"", ""start_span"": 136, ""end_span"": 143, ""type"": ""Gene_or_gene_product""}, {""token"": ""p65"", ""start_span"": 147, ""end_span"": 150, ""type"": ""Gene_or_gene_product""}, {""token"": ""rhTNF - alpha"", ""start_span"": 169, ""end_span"": 182, ""type"": ""Gene_or_gene_product""}]"
Furthermore, suppression of NF - kappaB activation decreased the transcript levels and BMP - 2 - induced phosphorylation of Smad1 / 5 / 8, critical downstream targets of BMP - 2 signaling in PC cells.	"NF - kappaB	28	39	Gene_or_gene_product"	"BMP - 2	87	94	Gene_or_gene_product"	"Smad1	124	129	Gene_or_gene_product"	"5	132	133	Gene_or_gene_product"	"8	136	137	Gene_or_gene_product"	"BMP - 2	170	177	Gene_or_gene_product"	"[{""token"": ""NF - kappaB"", ""start_span"": 28, ""end_span"": 39, ""type"": ""Gene_or_gene_product""}, {""token"": ""BMP - 2"", ""start_span"": 87, ""end_span"": 94, ""type"": ""Gene_or_gene_product""}, {""token"": ""Smad1"", ""start_span"": 124, ""end_span"": 129, ""type"": ""Gene_or_gene_product""}, {""token"": ""5"", ""start_span"": 132, ""end_span"": 133, ""type"": ""Gene_or_gene_product""}, {""token"": ""8"", ""start_span"": 136, ""end_span"": 137, ""type"": ""Gene_or_gene_product""}, {""token"": ""BMP - 2"", ""start_span"": 170, ""end_span"": 177, ""type"": ""Gene_or_gene_product""}]"
Outcomes measures included transcutaneous blood gas levels, histology, total RNA content and analysis of alpha2 ( I) collagen ( COL - I), type IV collagen ( COL - IV), alpha1 ( V) collagen ( COL - V), and vascular endothelial growth factor ( VEGF) expression using real - time quantitative PCR.	"COL - I	128	135	Gene_or_gene_product"	"type IV collagen	138	154	Gene_or_gene_product"	"COL - IV	157	165	Gene_or_gene_product"	"COL - V	191	198	Gene_or_gene_product"	"vascular endothelial growth factor	205	239	Gene_or_gene_product"	"VEGF	242	246	Gene_or_gene_product"	"[{""token"": ""COL - I"", ""start_span"": 128, ""end_span"": 135, ""type"": ""Gene_or_gene_product""}, {""token"": ""type IV collagen"", ""start_span"": 138, ""end_span"": 154, ""type"": ""Gene_or_gene_product""}, {""token"": ""COL - IV"", ""start_span"": 157, ""end_span"": 165, ""type"": ""Gene_or_gene_product""}, {""token"": ""COL - V"", ""start_span"": 191, ""end_span"": 198, ""type"": ""Gene_or_gene_product""}, {""token"": ""vascular endothelial growth factor"", ""start_span"": 205, ""end_span"": 239, ""type"": ""Gene_or_gene_product""}, {""token"": ""VEGF"", ""start_span"": 242, ""end_span"": 246, ""type"": ""Gene_or_gene_product""}]"
OBJECTIVES: Strategies to inhibit the VEGF pathway, including antibodies to VEGF, antibodies to the extracellular domain of VEGFR - 1 or VEGFR - 2, decoy receptors for VEGF and tyrosine kinase inhibitors of VEGFRs, are summarized.	"VEGF	38	42	Gene_or_gene_product"	"antibodies to VEGF	62	80	Gene_or_gene_product"	"antibodies to the extracellular domain of VEGFR - 1	82	133	Gene_or_gene_product"	"VEGFR - 2	137	146	Gene_or_gene_product"	"VEGF	168	172	Gene_or_gene_product"	"VEGFRs	207	213	Gene_or_gene_product"	"[{""token"": ""VEGF"", ""start_span"": 38, ""end_span"": 42, ""type"": ""Gene_or_gene_product""}, {""token"": ""antibodies to VEGF"", ""start_span"": 62, ""end_span"": 80, ""type"": ""Gene_or_gene_product""}, {""token"": ""antibodies to the extracellular domain of VEGFR - 1"", ""start_span"": 82, ""end_span"": 133, ""type"": ""Gene_or_gene_product""}, {""token"": ""VEGFR - 2"", ""start_span"": 137, ""end_span"": 146, ""type"": ""Gene_or_gene_product""}, {""token"": ""VEGF"", ""start_span"": 168, ""end_span"": 172, ""type"": ""Gene_or_gene_product""}, {""token"": ""VEGFRs"", ""start_span"": 207, ""end_span"": 213, ""type"": ""Gene_or_gene_product""}]"
Semaphorin 7A ( Sema7A) is a membrane - linked semaphorin that is expressed by human keratinocytes, and we have shown that Sema7A binds to human melanocytes through beta1 - integrins and the Plexin C1 receptor.	"Semaphorin 7A	0	13	Gene_or_gene_product"	"Sema7A	16	22	Gene_or_gene_product"	"semaphorin	47	57	Gene_or_gene_product"	"Sema7A	123	129	Gene_or_gene_product"	"beta1 - integrins	165	182	Gene_or_gene_product"	"Plexin C1 receptor	191	209	Gene_or_gene_product"	"[{""token"": ""Semaphorin 7A"", ""start_span"": 0, ""end_span"": 13, ""type"": ""Gene_or_gene_product""}, {""token"": ""Sema7A"", ""start_span"": 16, ""end_span"": 22, ""type"": ""Gene_or_gene_product""}, {""token"": ""semaphorin"", ""start_span"": 47, ""end_span"": 57, ""type"": ""Gene_or_gene_product""}, {""token"": ""Sema7A"", ""start_span"": 123, ""end_span"": 129, ""type"": ""Gene_or_gene_product""}, {""token"": ""beta1 - integrins"", ""start_span"": 165, ""end_span"": 182, ""type"": ""Gene_or_gene_product""}, {""token"": ""Plexin C1 receptor"", ""start_span"": 191, ""end_span"": 209, ""type"": ""Gene_or_gene_product""}]"
Since Akt phosphorylates Chk1 - Ser ( 280), the effect of Erbb2 on phosphatidyl inositol - 3 - kinase ( PI3K) / Akt signaling during UV - induced cell cycle arrest was determined.	"Akt	6	9	Gene_or_gene_product"	"Chk1	25	29	Gene_or_gene_product"	"Erbb2	58	63	Gene_or_gene_product"	"phosphatidyl inositol - 3 - kinase	67	101	Gene_or_gene_product"	"PI3K	104	108	Gene_or_gene_product"	"Akt	112	115	Gene_or_gene_product"	"[{""token"": ""Akt"", ""start_span"": 6, ""end_span"": 9, ""type"": ""Gene_or_gene_product""}, {""token"": ""Chk1"", ""start_span"": 25, ""end_span"": 29, ""type"": ""Gene_or_gene_product""}, {""token"": ""Erbb2"", ""start_span"": 58, ""end_span"": 63, ""type"": ""Gene_or_gene_product""}, {""token"": ""phosphatidyl inositol - 3 - kinase"", ""start_span"": 67, ""end_span"": 101, ""type"": ""Gene_or_gene_product""}, {""token"": ""PI3K"", ""start_span"": 104, ""end_span"": 108, ""type"": ""Gene_or_gene_product""}, {""token"": ""Akt"", ""start_span"": 112, ""end_span"": 115, ""type"": ""Gene_or_gene_product""}]"
We have shown that Arf6 and its effector AMAP1 ( DDEF1, DEF1, ASAP1 and centaurin beta4) are abnormally overexpressed in some breast cancers and used for their invasion and metastasis.	"Arf6	19	23	Gene_or_gene_product"	"AMAP1	41	46	Gene_or_gene_product"	"DDEF1	49	54	Gene_or_gene_product"	"DEF1	56	60	Gene_or_gene_product"	"ASAP1	62	67	Gene_or_gene_product"	"centaurin beta4	72	87	Gene_or_gene_product"	"[{""token"": ""Arf6"", ""start_span"": 19, ""end_span"": 23, ""type"": ""Gene_or_gene_product""}, {""token"": ""AMAP1"", ""start_span"": 41, ""end_span"": 46, ""type"": ""Gene_or_gene_product""}, {""token"": ""DDEF1"", ""start_span"": 49, ""end_span"": 54, ""type"": ""Gene_or_gene_product""}, {""token"": ""DEF1"", ""start_span"": 56, ""end_span"": 60, ""type"": ""Gene_or_gene_product""}, {""token"": ""ASAP1"", ""start_span"": 62, ""end_span"": 67, ""type"": ""Gene_or_gene_product""}, {""token"": ""centaurin beta4"", ""start_span"": 72, ""end_span"": 87, ""type"": ""Gene_or_gene_product""}]"
CONCLUSION: Osteopontin siRNA can inhibit U251 cells invasion via the down - regulation of uPA, MMP - 2 and MMP - 9 levels, and promote apoptosis through induction of Bax expression and inhibition of Bcl 2 level.	"Osteopontin	12	23	Gene_or_gene_product"	"uPA	91	94	Gene_or_gene_product"	"MMP - 2	96	103	Gene_or_gene_product"	"MMP - 9	108	115	Gene_or_gene_product"	"Bax	167	170	Gene_or_gene_product"	"Bcl 2	200	205	Gene_or_gene_product"	"[{""token"": ""Osteopontin"", ""start_span"": 12, ""end_span"": 23, ""type"": ""Gene_or_gene_product""}, {""token"": ""uPA"", ""start_span"": 91, ""end_span"": 94, ""type"": ""Gene_or_gene_product""}, {""token"": ""MMP - 2"", ""start_span"": 96, ""end_span"": 103, ""type"": ""Gene_or_gene_product""}, {""token"": ""MMP - 9"", ""start_span"": 108, ""end_span"": 115, ""type"": ""Gene_or_gene_product""}, {""token"": ""Bax"", ""start_span"": 167, ""end_span"": 170, ""type"": ""Gene_or_gene_product""}, {""token"": ""Bcl 2"", ""start_span"": 200, ""end_span"": 205, ""type"": ""Gene_or_gene_product""}]"
Sunitinib induces apoptosis in pheochromocytoma tumor cells by inhibiting VEGFR2 / Akt / mTOR / S6K1 pathways through modulation of Bcl - 2 and BAD.	"VEGFR2	74	80	Gene_or_gene_product"	"Akt	83	86	Gene_or_gene_product"	"mTOR	89	93	Gene_or_gene_product"	"S6K1	96	100	Gene_or_gene_product"	"Bcl - 2	132	139	Gene_or_gene_product"	"BAD	144	147	Gene_or_gene_product"	"[{""token"": ""VEGFR2"", ""start_span"": 74, ""end_span"": 80, ""type"": ""Gene_or_gene_product""}, {""token"": ""Akt"", ""start_span"": 83, ""end_span"": 86, ""type"": ""Gene_or_gene_product""}, {""token"": ""mTOR"", ""start_span"": 89, ""end_span"": 93, ""type"": ""Gene_or_gene_product""}, {""token"": ""S6K1"", ""start_span"": 96, ""end_span"": 100, ""type"": ""Gene_or_gene_product""}, {""token"": ""Bcl - 2"", ""start_span"": 132, ""end_span"": 139, ""type"": ""Gene_or_gene_product""}, {""token"": ""BAD"", ""start_span"": 144, ""end_span"": 147, ""type"": ""Gene_or_gene_product""}]"
Thus, these results together suggest that sunitinib initially exerts its apoptotic effect through the inhibition of VEGFR - 2, which, when followed by reduction of its downstream effectors, including Akt / mTOR / S6K1, may lead to inhibition of the antiapoptotic molecule Bcl - 2 and activation of the proapoptotic molecule BAD in PC12 cells.	"VEGFR - 2	116	125	Gene_or_gene_product"	"Akt	200	203	Gene_or_gene_product"	"mTOR	206	210	Gene_or_gene_product"	"S6K1	213	217	Gene_or_gene_product"	"Bcl - 2	272	279	Gene_or_gene_product"	"BAD	324	327	Gene_or_gene_product"	"[{""token"": ""VEGFR - 2"", ""start_span"": 116, ""end_span"": 125, ""type"": ""Gene_or_gene_product""}, {""token"": ""Akt"", ""start_span"": 200, ""end_span"": 203, ""type"": ""Gene_or_gene_product""}, {""token"": ""mTOR"", ""start_span"": 206, ""end_span"": 210, ""type"": ""Gene_or_gene_product""}, {""token"": ""S6K1"", ""start_span"": 213, ""end_span"": 217, ""type"": ""Gene_or_gene_product""}, {""token"": ""Bcl - 2"", ""start_span"": 272, ""end_span"": 279, ""type"": ""Gene_or_gene_product""}, {""token"": ""BAD"", ""start_span"": 324, ""end_span"": 327, ""type"": ""Gene_or_gene_product""}]"
IL - 17F ablation decreased IL - 1beta and Cox - 2 expression as well as IL - 17 receptor C ( IL - 17RC) expression, which were increased in tumors from Apc ( Min / +) mice.	"IL - 17F	0	8	Gene_or_gene_product"	"IL - 1beta	28	38	Gene_or_gene_product"	"Cox - 2	43	50	Gene_or_gene_product"	"IL - 17 receptor C	73	91	Gene_or_gene_product"	"IL - 17RC	94	103	Gene_or_gene_product"	"Apc	153	156	Gene_or_gene_product"	"[{""token"": ""IL - 17F"", ""start_span"": 0, ""end_span"": 8, ""type"": ""Gene_or_gene_product""}, {""token"": ""IL - 1beta"", ""start_span"": 28, ""end_span"": 38, ""type"": ""Gene_or_gene_product""}, {""token"": ""Cox - 2"", ""start_span"": 43, ""end_span"": 50, ""type"": ""Gene_or_gene_product""}, {""token"": ""IL - 17 receptor C"", ""start_span"": 73, ""end_span"": 91, ""type"": ""Gene_or_gene_product""}, {""token"": ""IL - 17RC"", ""start_span"": 94, ""end_span"": 103, ""type"": ""Gene_or_gene_product""}, {""token"": ""Apc"", ""start_span"": 153, ""end_span"": 156, ""type"": ""Gene_or_gene_product""}]"
Furthermore, rat mammary carcinomas with elevated neu expression ( neu - induced) also had sharply elevated LAR - PTPase expression when compared to rat mammary carcinomas with little or no neu expression ( 7, 12 - dimethylbenzanthracene induced); the level of expression of LAR PTPase was directly correlated with the level of neu expression.	"neu	50	53	Gene_or_gene_product"	"neu	67	70	Gene_or_gene_product"	"LAR - PTPase	108	120	Gene_or_gene_product"	"neu	190	193	Gene_or_gene_product"	"LAR PTPase	275	285	Gene_or_gene_product"	"neu	328	331	Gene_or_gene_product"	"[{""token"": ""neu"", ""start_span"": 50, ""end_span"": 53, ""type"": ""Gene_or_gene_product""}, {""token"": ""neu"", ""start_span"": 67, ""end_span"": 70, ""type"": ""Gene_or_gene_product""}, {""token"": ""LAR - PTPase"", ""start_span"": 108, ""end_span"": 120, ""type"": ""Gene_or_gene_product""}, {""token"": ""neu"", ""start_span"": 190, ""end_span"": 193, ""type"": ""Gene_or_gene_product""}, {""token"": ""LAR PTPase"", ""start_span"": 275, ""end_span"": 285, ""type"": ""Gene_or_gene_product""}, {""token"": ""neu"", ""start_span"": 328, ""end_span"": 331, ""type"": ""Gene_or_gene_product""}]"
